Free Trial

NKGen Biotech (NKGN) Competitors

NKGen Biotech logo
$0.64 +0.07 (+13.25%)
(As of 12/20/2024 05:31 PM ET)

NKGN vs. INCR, ONCY, CUE, BYSI, VNRX, ATRA, CNTB, SPRO, AADI, and MURA

Should you be buying NKGen Biotech stock or one of its competitors? The main competitors of NKGen Biotech include InterCure (INCR), Oncolytics Biotech (ONCY), Cue Biopharma (CUE), BeyondSpring (BYSI), VolitionRx (VNRX), Atara Biotherapeutics (ATRA), Connect Biopharma (CNTB), Spero Therapeutics (SPRO), Aadi Bioscience (AADI), and Mural Oncology (MURA). These companies are all part of the "pharmaceutical products" industry.

NKGen Biotech vs.

InterCure (NASDAQ:INCR) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, community ranking, dividends and earnings.

InterCure has higher revenue and earnings than NKGen Biotech.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InterCure$272.67M0.25-$16.83MN/AN/A
NKGen Biotech$80K282.90-$82.94M-$5.08-0.13

Company Net Margins Return on Equity Return on Assets
InterCureN/A N/A N/A
NKGen Biotech N/A N/A -479.36%

8.3% of InterCure shares are owned by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are owned by institutional investors. 0.2% of InterCure shares are owned by insiders. Comparatively, 74.7% of NKGen Biotech shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

InterCure received 3 more outperform votes than NKGen Biotech when rated by MarketBeat users.

CompanyUnderperformOutperform
InterCureOutperform Votes
3
100.00%
Underperform Votes
No Votes
NKGen BiotechN/AN/A

InterCure has a beta of 1.37, indicating that its share price is 37% more volatile than the S&P 500. Comparatively, NKGen Biotech has a beta of 0.77, indicating that its share price is 23% less volatile than the S&P 500.

In the previous week, InterCure had 2 more articles in the media than NKGen Biotech. MarketBeat recorded 2 mentions for InterCure and 0 mentions for NKGen Biotech. InterCure's average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company Overall Sentiment
InterCure Neutral
NKGen Biotech Neutral

Summary

InterCure beats NKGen Biotech on 6 of the 9 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NKGN vs. The Competition

MetricNKGen BiotechBiological Products IndustryMedical SectorNYSE Exchange
Market Cap$22.63M$2.94B$5.12B$19.18B
Dividend YieldN/A1.90%4.91%3.59%
P/E Ratio-0.1346.7391.3441.28
Price / Sales282.90411.851,116.5917.59
Price / CashN/A182.1042.6421.28
Price / Book-0.243.894.795.32
Net Income-$82.94M-$42.21M$120.07M$989.88M
7 Day Performance28.05%-2.14%-1.89%-3.54%
1 Month Performance89.57%4.21%11.45%-3.68%
1 Year Performance-77.39%18.40%30.61%12.14%

NKGen Biotech Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NKGN
NKGen Biotech
N/A$0.64
+13.3%
N/A-78.2%$22.63M$80,000.00-0.13N/AGap Up
INCR
InterCure
0.1035 of 5 stars
$1.42
+7.8%
N/A+16.4%$64.71M$272.67M0.00350News Coverage
Gap Up
ONCY
Oncolytics Biotech
1.9125 of 5 stars
$0.83
+1.4%
$4.00
+384.8%
-33.0%$63.58MN/A0.0030News Coverage
CUE
Cue Biopharma
4.687 of 5 stars
$1.00
+6.4%
$5.00
+400.0%
-63.1%$63.36M$9.53M-1.0360News Coverage
Positive News
BYSI
BeyondSpring
N/A$1.60
-2.7%
N/A+72.8%$62.25M$1.88M0.0080Positive News
Gap Down
VNRX
VolitionRx
1.7492 of 5 stars
$0.67
+18.6%
$3.75
+459.7%
+2.4%$62.09M$770,000.00-1.5780Gap Up
ATRA
Atara Biotherapeutics
3.8375 of 5 stars
$10.68
+3.4%
$16.67
+56.1%
-17.6%$61.52M$100.44M-0.40165Analyst Forecast
News Coverage
Gap Up
CNTB
Connect Biopharma
3.4741 of 5 stars
$1.08
-3.4%
$8.00
+640.7%
+11.9%$59.68M$24.12M0.00110Positive News
Gap Down
SPRO
Spero Therapeutics
4.5453 of 5 stars
$1.09
+1.9%
$5.00
+358.7%
-29.3%$59.43M$103.78M15.2946Analyst Downgrade
News Coverage
AADI
Aadi Bioscience
1.6265 of 5 stars
$2.37
-1.7%
$1.67
-29.7%
+64.6%$58.41M$25.07M-1.0640News Coverage
Gap Up
MURA
Mural Oncology
3.0856 of 5 stars
$3.41
-6.3%
$16.00
+369.2%
-9.1%$58.04MN/A-0.40119Negative News
Gap Up

Related Companies and Tools


This page (NYSE:NKGN) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners